LOC440338 Inhibitors
The term LOC440338 Inhibitors denotes a specific category of chemical compounds designed to modulate the activity of LOC440338, a molecular target currently under scrutiny in scientific research. These inhibitors are meticulously crafted through the principles of medicinal chemistry, aiming to selectively interfere with the normal functions of LOC440338 within cellular processes. The structural composition of LOC440338 Inhibitors undergoes a meticulous optimization process, incorporating computational modeling and structure-activity relationship studies to fine-tune their molecular configurations for effective binding to the target.
The significance of LOC440338 Inhibitors lies in their potential to disrupt the biochemical activities associated with LOC440338, a presumed participant in various biological pathways. Researchers in this field delve into the three-dimensional structure of LOC440338 and its binding interactions with inhibitors, seeking to unravel the intricate molecular mechanisms that underlie inhibition. The study of LOC440338 Inhibitors contributes to a broader understanding of cellular processes, offering insights into the roles played by LOC440338 in diverse biological pathways and expanding our knowledge of the regulatory networks governing cellular activities. This research not only advances our comprehension of the molecular intricacies surrounding LOC440338 but also contributes to the broader scientific understanding of molecular targets and their involvement in fundamental cellular functions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride (LiCl) is known to inhibit GSK-3β, a kinase in the Wnt signaling pathway. Inhibition of GSK-3β could lead to downstream effects on genes regulated by Wnt, possibly including SHISA9. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid has regulatory effects on gene expression through its role as an active metabolite of vitamin A, influencing cellular processes and developmental pathways that might include the expression of SHISA9. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is part of the MAPK/ERK pathway. Inhibition of this pathway could affect the transcriptional regulation of genes involved in development, potentially including SHISA9. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of the TGF-β receptor. TGF-β signaling affects numerous developmental processes and gene expression patterns, including potentially that of SHISA9. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine inhibits the Hedgehog signaling pathway by targeting the Smoothened receptor. While not directly linked to SHISA9, Hedgehog pathway regulation could influence the expression of developmental genes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could disrupt downstream AKT signaling, thereby potentially impacting gene expression patterns, including SHISA9, if related to the PI3K/AKT pathway. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
This compound is a DNA methyltransferase inhibitor and could lead to hypomethylation of gene promoters, potentially increasing the expression of certain genes while inhibiting others, depending on the specific regulatory context of SHISA9. | ||||||
Zebularine | 3690-10-6 | sc-203315 sc-203315A sc-203315B | 10 mg 25 mg 100 mg | $129.00 $284.00 $1004.00 | 3 | |
Zebularine is a cytidine analog that traps DNA methyltransferases, potentially leading to demethylation of DNA and altered gene expression. Its effects on SHISA9 expression would depend on the methylation status of regulatory regions of the SHISA9 gene. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a γ-secretase inhibitor that can block Notch signaling, a pathway that regulates cellular differentiation. Inhibition of Notch signaling could potentially alter the expression of developmental genes, including SHISA9. | ||||||
SU 5402 | 215543-92-3 | sc-204308 sc-204308A | 1 mg 5 mg | $63.00 $98.00 | 36 | |
SU5402 is a potent and selective inhibitor of FGF receptor tyrosine kinase which is involved in the regulation of embryonic development. If SHISA9 is part of the FGF signaling pathway, SU5402 could influence its expression. | ||||||